Mechanisms of Gulf War Illness
NCT05972291 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80
Last updated 2025-12-05
Summary
Many veterans with Gulf War Illness developed chronic gastrointestinal symptoms during their deployment to the Persian Gulf. The pathophysiologic mechanisms of these chronic gastrointestinal symptoms are not well understood but cause significant morbidity in veterans. Our proposed studies will provide an innovative and novel treatment trial for chronic gastrointestinal symptoms in veterans with Gulf War Illness that were deployed into war zones. Given that there are currently no specific treatments for these disorders, and that current symptomatic approaches are far from ideal, proof of principle of our trial would be an extremely important advance as it would not only have a beneficial impact on the health of many thousands of our veterans, but also it would substantially reduce the many negative economic effects of this ailment on the VA Health Care System.
Conditions
- Gulf War Illness
- Irritable Bowel Syndrome
- Gastrointestinal Symptoms
Interventions
- DIETARY_SUPPLEMENT
-
Oral Glutamine
You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
- OTHER
-
Control Arm
You will receive an unmarked packet with either glutamine or whey protein powder. Once the packet is opened, the powder should be mixed completely with 8 oz of water. You should completely drink this mixture within 10 minutes. You will consume one packet three times a day for 12 weeks. One packet 30 minutes before breakfast, one packet 30 minutes before lunch, and one packet 30 minutes before the evening meal.
Sponsors & Collaborators
-
VA Office of Research and Development
lead FED
Principal Investigators
-
QiQi Zhou, MD PhD · Memphis VA Medical Center, Memphis, TN
-
George N Verne · Memphis VA Medical Center, Memphis, TN
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-10-16
- Primary Completion
- 2026-07-30
- Completion
- 2027-07-31
Countries
- United States
Study Locations
More Related Trials
-
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
NCT02980406 ·Status: COMPLETED ·Phase: NA
-
Elemental Diet and Gut Microbiome
NCT05978973 ·Status: COMPLETED ·Phase: NA
-
A Practice Change for Patients With Severe Chronic, Clinically Unexplained Gastrointestinal Symptoms
NCT05274854 ·Status: RECRUITING ·Phase: NA
-
Glutamine for the Treatment of Patients With Irritable Bowel Syndrome
NCT01414244 ·Status: COMPLETED ·Phase: PHASE2
-
Change in Permeability of the Small Intestine After Treatment With Gluten
NCT02098057 ·Status: COMPLETED ·Phase: NA
-
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
NCT03266068 ·Status: COMPLETED
-
Gluten-free Diet in Irritable Bowel Syndrome
NCT02528929 ·Status: COMPLETED ·Phase: NA
-
Delivered Dietary Intervention for Children With Irritable Bowel Syndrome
NCT01339117 ·Status: COMPLETED ·Phase: NA
-
Impact of Diet on Functional Gastrointestinal Symptoms
NCT03102411 ·Status: COMPLETED
-
Analysis of Microbiota Changes Induced by Microencapsulated Sodium Butyrate in Patients With Inflammatory Bowel Disease
NCT04879914 ·Status: COMPLETED ·Phase: NA
-
Acute Gastrointestinal Tolerability Following a Single Serving of a Novel Dietary Fiber
NCT02530762 ·Status: COMPLETED ·Phase: NA
-
Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome
NCT02249169 ·Status: COMPLETED
-
Vitamin B6 Aids in Treating Inflammatory Bowel Disease
NCT06512441 ·Status: RECRUITING ·Phase: NA
-
Efficacy of Glutamine Supplementation in Patients Suffering From Irritable Bowel Syndrome With Impaired Intestinal Permeability
NCT06291038 ·Status: RECRUITING ·Phase: NA
-
Neural Circuit Mechanism of Inflammatory Bowel Disease Combined With Depression
NCT06471894 ·Status: NOT_YET_RECRUITING
-
Gut Peptides and Intestinal Permeability in Celiac Disease and Irritable Bowel Syndrome
NCT01574209 ·Status: COMPLETED
-
Reliability of a Food Frequency Questionnaire in the Assessment of Dietary Intake Including FODMAPs in Different Populations, and Relationship With IBS Symptoms and the Degree of Self-assessed Physical Activity
NCT05293769 ·Status: RECRUITING
-
Irritable Bowel Syndrome and Food Sensitivity
NCT02186743 ·Status: COMPLETED ·Phase: NA
-
The Expression of the Ionotropic Glutamate Receptors in Colon of IBS
NCT02512146 ·Status: UNKNOWN
-
Comparing Two Types of Diets on Psychological and Gastrointestinal Symptoms
NCT03035799 ·Status: COMPLETED ·Phase: NA
-
Marine Protein Hydrolysate as Dietary Supplement in Irritable Bowel Syndrome
NCT03801057 ·Status: COMPLETED ·Phase: NA
-
The Effectiveness of Temple Stay in Irritable Bowel Syndrome
NCT05999500 ·Status: RECRUITING
-
Mediterranean Diet and the Gut Microbiome
NCT03269032 ·Status: COMPLETED ·Phase: NA
-
Gut Permeability, Sensitivity and Symptomatology
NCT02358564 ·Status: COMPLETED ·Phase: NA
-
ConfocAl endomicroSCopy bAsed Diet Trial in IBS
NCT05097872 ·Status: RECRUITING ·Phase: NA